Wednesday, July 8, 2026

pharma · Epilepsy · Attention-Deficit/Hyperactivity Disorder (ADHD) · SUPN

SUPERNUS PHARMACEUTICALS

SUPERNUS PHARMACEUTICALS is a pharma organization headquartered in Rockville, USA. It trades on NYSE under ticker SUPN. Primary therapeutic focus areas include Epilepsy, Attention-Deficit/Hyperactivity Disorder (ADHD), P

9715 Key West Ave, Rockville, Maryland 20850, US HQ
2005 Founded
828 Employees
Public company Type
SUPN · NYSE Ticker
Company details
Status
Public
HQ
9715 Key West Ave, Rockville, Maryland 20850, US
Founded
2005
Employees
828
Programs
55
Drugs
25
Patents
68
Clinical program

BIS-001 ER

Phase 1 · small molecule · Epilepsy, Complex Partial

BIS-001 ER for Epilepsy, Complex Partial is a Phase 1 program (small_molecule) at SUPERNUS PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

← All SUPERNUS PHARMACEUTICALS, INC. projects Phase 1 small molecule completed

Internal code BNI-01-1b

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
SUPERNUS PHARMACEUTICALS, INC.
Phase
Phase 1
Modality
small_molecule
Indication
Epilepsy, Complex Partial
Status
completed
Trials
1

Clinical trials